NASDAQ · IFRX
Healthcare · Biotechnology
$2.09
Down-$0.04 (-1.91%)
Updated Sep 10, 2026, 10:33 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IFRX closed at $2.09 after 20 trading sessions, up 3.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $2.15 | $2.15 | $2.05 | $2.09 | 759.75K |
| Sep 8, 2026 | $2.19 | $2.26 | $2.11 | $2.17 | 408.9K |
| Sep 4, 2026 | $2.21 | $2.3767 | $2.16 | $2.22 | 393.94K |
| Sep 3, 2026 | $2.30 | $2.3705 | $2.18 | $2.23 | 666.37K |
| Sep 2, 2026 | $2.16 | $2.34 | $2.1326 | $2.29 | 572.04K |
| Sep 1, 2026 | $2.12 | $2.27 | $2.09 | $2.16 | 475.08K |
| Aug 31, 2026 | $2.21 | $2.23 | $2.09 | $2.13 | 447.81K |
| Aug 28, 2026 | $2.28 | $2.37 | $2.21 | $2.23 | 610.42K |
| Aug 27, 2026 | $2.40 | $2.4349 | $2.245 | $2.27 | 1.41M |
| Aug 26, 2026 | $2.45 | $2.50 | $2.33 | $2.42 | 1.71M |
| Aug 25, 2026 | $2.06 | $2.46 | $2.01 | $2.46 | 3.89M |
| Aug 24, 2026 | $2.10 | $2.11 | $2.03 | $2.05 | 337.02K |
| Aug 21, 2026 | $2.03 | $2.12 | $2.025 | $2.10 | 419.9K |
| Aug 20, 2026 | $2.12 | $2.15 | $2.005 | $2.02 | 587.74K |
| Aug 19, 2026 | $2.18 | $2.22 | $2.09 | $2.12 | 958.32K |
| Aug 18, 2026 | $2.05 | $2.18 | $2.035 | $2.18 | 556.58K |
| Aug 17, 2026 | $2.04 | $2.095 | $2.03 | $2.07 | 564.83K |
| Aug 14, 2026 | $2.01 | $2.05 | $1.92 | $2.04 | 1.47M |
| Aug 13, 2026 | $2.02 | $2.055 | $1.965 | $2.01 | 1.9M |
| Aug 12, 2026 | $1.99 | $2.06 | $1.93 | $2.01 | 1.57M |
The latest Smart Investors Daily articles mentioning IFRX.
IFRX research
Company profile and research snapshot.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| May 13, 2026 | Raymond James | Strong Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| May 11, 2026 | Cantor Fitzgerald | Overweight | — |
| Apr 21, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 3, 2026
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares increased by
Benzinga · Aug 7, 2026
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
ChartMill · Aug 6, 2026
InflaRx Q2 2026 misses estimates; EPS -$0.095 vs -$0.060, revenue nil. Stock falls pre-market but pipeline advances with izicopan.
Benzinga · Aug 6, 2026
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per share from the same
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IFRX.
No results
No recent SID articles mention IFRX.
